信迪利单抗、贝伐珠单抗联合化疗对非小细胞肺癌治疗效果及对患者生活质量的影响

Therapeutic Efficacy of Sintilimab and Bevacizumab Combined with Chemotherapy in Non-small Cell Lung Cancer and the Impact on Patients'Quality of Life

目的 研究信迪利单抗、贝伐珠单抗联合化疗对非小细胞肺癌治疗效果及对患者生活质量的影响。方法 选取淄博市第四人民医院于2020年4月—2023年1月收治的59例非小细胞肺癌住院患者作为研究对象,采用单双数随机法分为观察组(n=29)与对照组(n=30)。观察组采用信迪利单抗、贝伐珠单抗联合化疗治疗,对照组采用信迪利单抗联合化疗治疗,对比两组患者的客观反应有效率(Objective Response Rate, ORR)、病情控制率(Disease Control Rate, DCR)、生命质量、不良反应发生率。结果 观察组的ORR与DCR高于对照组,差异有统计学意义(P均<0.05);治疗后,两组患者的生命质量各维度均有不同程度的提高,且观察组各项指标均优于对照组,差异有统计学意义(P均<0.05);观察组患者不良反应总发生率为24.14%,低于对照组的53.33%,差异有统计学意义(χ^(2)=11.098,P<0.05)。结论 对非小细胞肺癌患者采取信迪利单抗、贝伐珠单抗联合化疗治疗,能够提高有效率,提高疾病控制,提升患者生命质量,且不良反应较少。

Objective To study the therapeutic effect of sintilimab and bevacizumab combined with chemotherapy on non-small cell lung cancer and the effect on patients'quality of life.Methods A total of 59 hospitalized patients with non-small cell lung cancer admitted to Zibo Fourth People's Hospital from April 2020 to January 2023 were selected as the study subjects,and were divided into the observation group(n=29)and the control group(n=30)by using single-double-number randomization method.The observation group was treated with the combination chemotherapy of sintilimab and bevacizumab,and the control group was treated with the combination chemotherapy of sintilimab.Objective response rate(ORR),disease control rate(DCR),quality of life,and incidence of adverse reactions were compared between the two groups.Results The ORR and DCR of the observation group were higher than those of the control group,and the differences were statistically significant(both P<0.05).After treatment,the quality of life of pa-tients in both groups improved to different degrees in all dimensions,and all indicators in the observation group were better than those in the control group,and the differences were statistically significant(all P<0.05).The incidence rate of adverse reactions in patients in the observation group was 24.14%,lower than 53.33%in the control group,and the differences were statistically significant(χ^(2)=11.098,P<0.05).Conclusion Adopting the combination chemotherapy of sintilimab and bevacizumab for non-small cell lung cancer patients can increase the efficiency,improve the disease control,and enhance the quality of life of patients,with less adverse reations.